Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

This study is currently recruiting participants.

Verified by HaEmek Medical Center, Israel, June 2007

First Received: June 19, 2007 Last Updated: June 20, 2007 History of Changes

Sponsor:	HaEmek Medical Center, Israel
Information provided by:	HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:	NCT00489723

Purpose

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.

Condition	Intervention
Kidney Stones	Drug: tamsulosin 0.4mg

Study Type:	Observational
Study Design:	Screening, Longitudinal, Defined Population, Prospective Study

Resource links provided by NLM:

Drug Information available for: Tamsulosin Tamsulosin hydrochloride

U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date:

May 2007

Eligibility

Ages Eligible for Study:	15 Years to 85 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

size of stone 1-2 cm

Exclusion Criteria:

ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00489723

Contacts

Contact: DORON PEREZ, M.D.

+972-4-6495115

perez_do@clalit.org.il

Locations

Israel
Haemek medical center	Recruiting
afula, Israel, 18100
Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il
Principal Investigator: doron perez, M.D.

Sponsors and Collaborators

HaEmek Medical Center, Israel

Investigators

Principal Investigator:

doron perez

Urology department: Haemek Medical Center

More Information

No publications provided

Study ID Numbers:	0056-07-EMC
Study First Received:	June 19, 2007
Last Updated:	June 20, 2007
ClinicalTrials.gov Identifier:	NCT00489723 History of Changes
Health Authority:	Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:

size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:

Pathological Conditions, Anatomical
Urinary Calculi
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Antineoplastic Agents
Urolithiasis
Physiological Effects of Drugs
Adrenergic alpha-Antagonists

Calculi
Pharmacologic Actions
Urologic Diseases
Therapeutic Uses
Tamsulosin
Adrenergic Antagonists
Kidney Diseases
Nephrolithiasis
Kidney Calculi

ClinicalTrials.gov processed this record on February 08, 2010